Avalo Therapeutics, Inc.
Avalo Therapeutics (Nasdaq: AVTX) reported Q2 2026 net loss of $36.4 million, or $0.83 per share, with no reported product revenue. Operating expenses rose to $31.5 million. Cash, cash equivalents and investments were $472.2 million as of June 30, 2026, and an equity offering generated about $405.0 million net proceeds. Shares closed $18.70 on Aug. 6.
Avalo Therapeutics (Nasdaq: AVTX) reported Q2 2026 results and business updates. The company plans to start a registrational Phase 3 for abdakibart in hidradenitis suppurativa in H1 2027 and expects to submit an IND for AVTX-010 in H1 2027. Cash, cash equivalents and investments were $472.2M at June 30, 2026, funding operations into 2029. Q2 net loss was $36.4M.
Avalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q2026earningsrelease.htm EX-99.1 Document Exhibit 99.1 Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates • Plans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the
Over the past 7 days, alphai's AI scored 3 news stories mentioning AVTX (Avalo Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent AVTX coverage spans earnings, corporate actions and financial news.
In the last 30 days, AVTX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($20K). The most active reporter was Doyle Mittie, Chief Medical Officer, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
The print is dilution- and burn-rate relevant, but the large cash balance and 2027 Phase 3 timing can cushion near-term downside.
The update is a clear de-risking step toward Phase 3 for abdakibart, plus an IND path for AVTX-010, supported by a stated cash runway into 2029.
The 8-K adds concrete clinical and funding runway milestones, supporting a higher-probability path to Phase 3 while increasing near-term R&D spend.
Board/compensation committee refresh via a new independent director with an equity grant; modest governance/catalyst impact rather than fundamentals.
The filing signals corporate governance updates plus a new preferred-stock instrument that can affect dilution, capital structure, and near-term financing overhang.
alphai scores every news story that mentions AVTX with an AI model for sentiment and relevance, and aggregates insider trades from Avalo Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Avalo Therapeutics (Nasdaq: AVTX) reported Q2 2026 net loss of $36.4 million, or $0.83 per share, with no reported product revenue. Operating expenses rose to $31.5 million. Cash, cash equivalents and investments were $472.2 million as of June 30, 2026, and an equity offering generated about $405.0 million net proceeds. Shares closed $18.70 on Aug. 6.
5 min readAvalo Therapeutics (Nasdaq: AVTX) reported Q2 2026 results and business updates. The company plans to start a registrational Phase 3 for abdakibart in hidradenitis suppurativa in H1 2027 and expects to submit an IND for AVTX-010 in H1 2027. Cash, cash equivalents and investments were $472.2M at June 30, 2026, funding operations into 2029. Q2 net loss was $36.4M.
6 min readAvalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q2026earningsrelease.htm EX-99.1 Document Exhibit 99.1 Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates • Plans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the
6 min readAvalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. avtx-20260623 0001534120 false 0001534120 2026-06-23 2026-06-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min readAvalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-3.1 2 ex-31certificateofdesignat.htm EX-3.1 Document Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES C-1 NON-VOTING CONVERTIBLE PREFERRED STOCK OF AVALO THERAPEUTICS, INC. Pursuant to Section 151 of the Delaware General Corporation Law Avalo Therapeutics, Inc., a Delaware cor
6 min readAvalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex-101arespp.htm EX-10.1 Document Exhibit 10.1 Avalo Therapeutics, Inc. Second Amended and Restated 2016 Employee Stock Purchase Plan Adopted by the Board of Directors: April 2, 2026 Approved by the Stockholders: June 2, 2026 1. General; Purpose. (a) The Plan provides a
3 min readDoyle Mittie (Chief Medical Officer) sold 679 shares of Avalo Therapeutics, Inc. (AVTX) at $16.00 on 2026-05-28 under a Rule 10b5-1 trading plan.
2 min readAvoro Capital Advisors LLC and Behzad Aghazadeh have reported a passive beneficial ownership of 1.41 million shares, or 5.75%, in Avalo Therapeutics (NASDAQ: AVTX) via a Schedule 13G filing. This disclosure indicates an investment purpose rather than an attempt to control the company. The percentage ownership is calculated based on 24,502,449 shares outstanding as of March 26, 2026, with the reporting persons holding sole voting and dispositive power over these shares.
2 min readAvalo Therapeutics (AVTX) reported a Q1 loss of $0.98 per share, which is better than the FactSet estimate of a $1.03 loss per share. The company is a clinical-stage biotechnology firm focusing on immune dysregulation, with lead asset AVTX-009 for inflammatory diseases.
2 min readAvalo Therapeutics, Inc. reported its first-quarter 2026 results, showing increased comprehensive and net losses compared to the previous year. This was attributed to higher spending on advancing clinical and regulatory programs. Financially, the company reported revenue of ($19.7M), net income of ($19.63M), and diluted EPS of ($0.98), alongside positive Phase 2 results for abdakibart and a significant follow-on offering to fund operations for several years.
4 min read
